Michael W. Bonney - Dec 27, 2023 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Role
Director
Signature
By: Stephen Hall, Attorney-in-Fact For: Michael W. Bonney
Stock symbol
ALNY
Transactions as of
Dec 27, 2023
Transactions value $
-$2,956,500
Form type
4
Date filed
12/29/2023, 04:03 PM
Previous filing
Aug 4, 2023
Next filing
May 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Options Exercise $2.89M +30K +187.16% $96.45 46K Dec 27, 2023 Direct F1
transaction ALNY Common Stock Sale -$5.85M -30K -65.18% $195.00 16K Dec 27, 2023 Direct F1
holding ALNY Common Stock 4K Dec 27, 2023 by Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALNY Stock Option (right to buy) Options Exercise $0 -30K -100% $0.00* 0 Dec 27, 2023 Common Stock 30K $96.45 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2023.
F2 The shares of ALNY common stock were purchased by the Michael W. Bonney Revocable Trust, of which the reporting person is trustee.
F3 The stock option was fully vested as of 12/17/2017.